<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908152</url>
  </required_header>
  <id_info>
    <org_study_id>467</org_study_id>
    <nct_id>NCT02908152</nct_id>
  </id_info>
  <brief_title>Curcumin Supplement in Nonalcoholic Fatty Liver Patients</brief_title>
  <official_title>The Effect of Curcumin Supplement on Metabolic Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of curcumin supplement on metabolic&#xD;
      factors and hepatic fibrosis in nonalcoholic fatty liver patients with type 2 diabetes.&#xD;
      Subjects will participate in 3 month, two group, randomized intervention, where one group&#xD;
      (n=25) will take 1.5g/d curcumin and the other group (n=25) will take a placebo to compare&#xD;
      differences in outcomes between the two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Actual">October 10, 2017</completion_date>
  <primary_completion_date type="Actual">July 10, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic steatosis</measure>
    <time_frame>[12 weeks]</time_frame>
    <description>measured by CAP score using Fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>[12 weeks]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBA1C</measure>
    <time_frame>[12 weeks]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>[12 weeks]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>[12 weeks]</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Nonalcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>curcumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>curcumin</intervention_name>
    <description>1500 mg&#xD;
1 capsule / day for 12 weeks</description>
    <arm_group_label>curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1500 mg&#xD;
1 capsule / day for 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient diagnosed with type 2 diabetes based on ADA definition or who only take oral&#xD;
             antidiabetic drug;&#xD;
&#xD;
          -  CAP score &gt;263.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking any kind of antibiotics two weeks before recruitment;&#xD;
&#xD;
          -  History of alcohol consumption;&#xD;
&#xD;
          -  pregnancy or lactation;&#xD;
&#xD;
          -  Professional athletes;&#xD;
&#xD;
          -  Other liver disease (viral/etc);&#xD;
&#xD;
          -  High dose synthetic estrogens, methotrexate, amiodarone, steroids, chloroquine,&#xD;
             immunosuppressive drugs;&#xD;
&#xD;
          -  A history of Cardiovascular disease;&#xD;
&#xD;
          -  Renal disease, Celiac disease, Cirrhosis;&#xD;
&#xD;
          -  History of Upper GI surgery;&#xD;
&#xD;
          -  A history of hypothyroidism or Cushing's syndrome;&#xD;
&#xD;
          -  History of drug dependence;&#xD;
&#xD;
          -  Body mass index (BMI) ≥35 kg/m2;&#xD;
&#xD;
          -  A restrictive diet or weight change ≥ 5 kg during the 3months prior to study;&#xD;
&#xD;
          -  Any change in treatment with oral hypoglycemic; anti hypertensive and antilipid agents&#xD;
             during the study;&#xD;
&#xD;
          -  Use of weight loss medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NNFTRI</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>September 26, 2020</last_update_submitted>
  <last_update_submitted_qc>September 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

